Introduction
The recognition that cancer is fundamentally a genetic disease 1, 2 , combined with an expanding repertoire of targeted small molecules [3] [4] [5] [6] [7] [8] , provides grounds for optimism that genome-based therapeutics may ultimately prove broadly applicable to human cancer. However, the rational deployment of targeted anti-cancer agents is often encumbered by an inability to identify a priori those tumors whose unique biology confers heightened susceptibility to a particular treatment.
Considerable insights into tumorigenesis have derived from functional studies involving cultured human cancer cells (e.g., established cell lines, short-term cultures, etc.); however, the overall relevance of tissue culture models to the complexities of in vivo tumor biology has often been questioned. Despite their limitations, cancer cell line collections whose genetic alterations reflect their primary tumor counterparts should nonetheless provide malleable proxies that facilitate mechanistic dissection and therapeutic development. Indeed, matched genomic and experimental data derived from these models may refine hypothesis generation and reveal new insights, as evidenced by recent studies 9, 10 . Such results may also be integrated with analogous data from clinical specimens to infer molecular subtypes and therapeutic vulnerabilities in tumors that manifest the relevant genomic changes [11] [12] [13] .
When it escapes early detection, malignant melanoma usually becomes a highly lethal malignancy that is refractory to existing therapeutic avenues 14, 15 . However, whereas many other solid tumors lack robust in vitro counterparts, melanoma offers an attractive experimental platform for systematic functional characterization of cancer genomic aberrations. Melanoma cells from patients with advanced disease proliferate readily in vitro; thus, hundreds of 'shortterm' melanoma cultures and established cell lines have been generated [16] [17] [18] . Melanoma shortterm cultures have typically undergone a relatively small number of passages outside of the patient, and the majority of these lines proliferate readily under standard laboratory conditions.
In principle, then, a cultured melanoma collection that reflects the diversity of genomic aberrations observed in primary melanomas should facilitate the characterization of critical and 'druggable' effectors linked to key molecular lesions in this malignancy.
Results

The genomic diversity of melanoma in vitro and in vivo
To enhance global knowledge of melanoma genomic alterations while also establishing a robust experimental system for downstream functional characterization, we generated comprehensive genomic data for 78 short-term melanoma cultures (median = 9 passages in vitro; range = 5-51), together with 11 established melanoma cell lines. Chromosomal copy number and loss-ofheterozygosity (LOH) alterations were examined using high-density single-nucleotide polymorphism (SNP) arrays 9, 19, 20 , and the mutation status of 17 known oncogenes was interrogated by Sanger sequencing or a mass spectrometry-based mutation profiling approach described previously 21 . Gene expression patterns were determined for 88 cultured melanoma lines and 5 normal melanocyte lines using a high-throughput microarray platform 22 (Affymetrix, Inc.; see Methods). Altogether, 118 cultured melanoma lines were examined by one or more of these platforms.
Since tumor chromosomal alterations are often non-focal, we next wished to predict which genetic changes represented statistically significant events (presumably enriched for "driver" alterations) in melanoma. To accomplish this, we employed an algorithm termed Genomic
Identification of Significant Targets in Cancer (GISTIC; Beroukhim et al., submitted) . This method systematically computes a significance score at each locus across the genome using smoothed microarray/CGH copy number data, based on the frequency and amplitude of each alteration (G score; see Methods). After permutation testing and multiple hypothesis correction, resulting false discovery rate (FDR)-corrected p values are plotted as a function of chromosomal location. Significant genomic regions of gain or loss are denoted by peaks in the GISTIC plot; the underlying chromosomal regions may then be inspected for candidate target genes.
The GISTIC output revealed thirteen major regions of significant copy number gain and fourteen regions of significant copy loss in the cultured melanoma collection (Figs. 1a and 1b; Tables 1   and 2 ). The most significant region of copy gain was located on chromosome 7q (Fig. 1a) . This locus harbors the BRAF oncogene, which contains activating point mutations in >50% of cutaneous melanomas 23 and in 60% of samples examined here. This suggests that mutated BRAF is also frequently amplified in melanoma. Additional prominent GISTIC copy gain peaks localized exquisitely to MITF, the master transcriptional regulator of melanocyte development and an amplified oncogene in 10-15% of melanomas 9 ; and to CCND1, a well-known oncogenic cell cycle regulator (Fig. 1a) . The most prominent region of copy loss spanned CDKN2A, an established melanoma tumor suppressor gene 24, 25 (Fig. 1b) . Aside from these expected findings, the majority of GISTIC peaks pinpointed genomic regions implicated previously in melanoma [26] [27] [28] ( Supplementary Fig. 1 ), but whose target genes remain largely unknown (Tables   1 and 2 ). Integration of sample-matched gene expression data enabled identification of candidate effector genes in several instances (Tables 1 and 2) . Thus, GISTIC analysis afforded a robust and unbiased means to identify key genomic loci whose target genes may contribute importantly to melanoma biology. These findings raised the possibility that deletions involving ERCC5 may contribute to melanoma genesis in the setting of chronic sun damage.
To confirm the similarities between cultured melanoma cells and primary melanomas, we performed pair-wise Pearson correlations between GISTIC plots of cultured melanoma data, primary melanomas, and a series of additional solid tumors whose chromosomal aberrations had been examined previously (Supplementary Table 1) . Notably, GISTIC correlations between cultured melanoma cells and primary cutaneous melanomas from non-CSD skin were stronger than any pair-wise coefficient observed among all other primary tumor sets, thereby providing a rigorous quantitative metric of genomic similarity. These data suggested that, in aggregate, cultured melanoma collections might provide a genetically appropriate model system for systematic functional genomic characterization.
Genome-wide measurements of loss-of-heterozygosity (LOH) in melanoma
High-density SNP arrays also enable inference of LOH 29 , even in the absence of matched normal DNA 30 . To identify significant LOH regions within our cultured melanoma collection, we predicted LOH patterns within each sample using a hidden Markov model 30 , and applied the GISTIC algorithm to the resulting LOH segments (see Methods). A strong concordance was observed between regions of LOH and copy loss (Fig. 1c) , suggesting that most melanoma LOH events occur by hemizygous deletion. The major exceptions to this pattern occurred at chromosomes 5q and 17p, where LOH in the absence of significant hemizygous deletion ("copy-neutral" LOH) was apparent. Although the relevant tumor suppressor at chromosome 5q
has not been identified, the LOH peak at chromosome 17p centers on the well-known TP53 tumor suppressor gene (Fig 1c) . This suggests that copy-neutral LOH may represent an important mechanism of p53 inactivation in melanoma. In a subset of short-term culture samples, a segment of chromosome 4q appeared to contain significant hemizygous deletion in the absence of LOH (Fig. 1c ). This unusual phenomenon, which could occur by whole genome duplication followed by copy loss and biallelic retention, implies that this region of the melanoma genome might be relatively refractory to LOH or uniparental disomy.
Molecular classification of melanoma based on chromosomal aberrations
We next sought to determine if significant chromosomal events might organize the melanoma samples into molecularly distinct and/or biologically relevant subsets. To address this, we applied established unsupervised learning methods 31 to the lesions identified by GISTIC (see deletions. NRAS mutations exhibited a higher prevalence in this subcluster than in cluster #3
( Fig. 2a) . Nonetheless, this cluster was also characterized by a high frequency of 7q gain, even in the setting of NRAS mutation, suggesting that BRAF-independent effectors located on chromosome 7q may also contribute to melanoma biology. A third group (n=20 samples) was characterized by a relative paucity of copy number alterations ("sparse"; Fig. 2a , cluster #1).
Finally, a relatively small branch (n = 13 samples, cluster #2) was moderately enriched for gains at 6p, 17q and 7p, and losses on 6q. Overall, these results suggested that GISTIC lesions may promote biologically relevant molecular groupings of melanoma tumor samples.
Predicting genes targeted by chromosome 10 deletions in melanoma
In melanoma, as in many solid tumors, most statistically significant chromosomal aberrations span large genomic regions whose target genes are unknown [26] [27] [28] . Among many other lesions, this pattern is exemplified by the gains and losses involving chromosomes 7 and 10, respectively-two prominent drivers of the GISTIC-based melanoma subclusters described above. Although the most significantly "amplified" region on chromosome 7 centers at 7q34
(contains BRAF; Fig. 1a ), most chromosome 10 copy losses cover the entire chromosome, punctuated by a more focal GISTIC peak at 10q23.31 ( (chromosome 10p14)-scored in this analysis, whereas PTEN failed to reach statistical significance ( Figure 3D ). CUL2 encodes a cullin protein whose yeast homologues negatively regulate the cell cycle 35 ; CUL2 also forms an E3 ubiquitin ligase complex with the VHL tumor suppressor protein 36, 37 . KLF6 encodes a zinc-finger transcription factor implicated as a tumor suppressor in several malignancies [38] [39] [40] . Thus, CUL2 and KLF6 represent intriguing candidate melanoma tumor suppressor genes targeted by chromosome 10 deletions.
Modifiers of RAF/MEK dependency in melanoma
The establishment of an experimentally tractable system reflective of melanoma genomic diversity provides a means to identify molecular predictors and modifiers of therapeutic response in this highly chemo-resistant malignancy. (Figure 4a) . Surprisingly, a shortterm culture harboring the BRAF K601E mutation also showed insensitivity to CI-1040. Together, these data suggested the presence of additional genetic or molecular modifiers of melanoma MAP kinase dependency apart from BRAF or NRAS mutation.
To investigate this in more detail, we examined the associated genomic and protein data in the melanoma lines described above. Despite the diversity of CI-1040 GI 50 values, a similar degree of target inhibition was evident in several representative lines, as measured by p-ERK immunoblotting studies (Supplementary Figure 4a) . A genome-wide analysis of correlated chromosomal alterations and expressed genes, summarized in Supplementary Figure 5 , was encumbered by the relatively small CI-1040-insensitive sample size (3 samples). However, two lines harboring the FGFR1 S125L mutation exhibited markedly enhanced sensitivity to MEK inhibition when compared to the A375 control cell line (Fig. 4b) . In contrast, 'steady-state' immunoblot analyses of MEK and ERK found that p-ERK levels were markedly elevated in all CI-1040-insensitive lines, with concomitant downregulation of total MEK protein in the three most resistant lines (Figure 4c ). These data suggest the intriguing possibility that novel signaling or feedback regulatory mechanisms may affect MAP kinase activation/dependency in melanoma, and that concomitant measurement of oncogene mutations and p-ERK levels may refine knowledge of melanoma patients likely to respond to targeted RAF or MEK inhibition.
Discussion
The unprecedented opportunities of cancer genomics also present new challenges to the identification of 'target-able' tumor mechanisms. In particular, characterizing the downstream effectors of common but often non-focal genomic alterations requires tractable in vitro models reflective of these genetic events. Our global genomic analyses indicate that melanoma shortterm cultures appear to encompass the spectrum of essential genomic diversity present in primary cutaneous melanomas, suggesting that these may offer a robust platform for functional genomic characterization. Moreover, the high-resolution statistical delineations enabled by the GISTIC analytical framework strongly suggests (but does not prove) that such regions contain genes whose perturbation contributes causally to melanoma genesis or maintenance.
These analytical refinements also call renewed attention to instances where a full chromosome or chromosome arm displays a common tumor-associated alteration. In melanoma, deletions and LOH involving chromosome 10 provide an instructive example. Several previous studies have implicated inactivation of the PTEN tumor suppressor gene as a key (epi)genetic event in melanoma. While our results support the notion that PTEN loss provides a driver alteration in some melanomas, they also suggest an alternative model wherein chromosome 10 losses provide a polygenic or otherwise PTEN-independent melanoma genesis mechanism(s).
Overall, the tendency towards large chromosomal perturbations in cancer underscores the future need for systematic functional studies in genetically-characterized tumor model systems.
Application of hierarchical clustering to a matrix of GISTIC lesions yields melanoma subclasses whose characteristics are suggestive of mechanistic relevance. When applied broadly in cancer genomics, these analyses may help reduce the complexity of cancer genome aberrations while also laying a robust groundwork for molecular classification and downstream functional approaches. In the future, genetically annotated melanoma lines could be subjected to systematic RNAi studies informed by GISTIC or related statistical information. Genes located within statistically credentialed genomic regions whose knockdown modulates a cancer phenotype of interest may illuminate 'druggable' cellular pathways linked to tumor genomic events identifiable in situ.
Finally, cell culture models reflective of in vivo tumor genetic diversity offer an attractive avenue to identify molecular features that modify the efficacy of therapeutic agents. In melanoma, the MAP kinase pathway is commonly activated by BRAF or NRAS oncogene point mutations, and BRAF(V600E) mutation is associated with sensitivity to RAF or MEK inhibition. Our data suggest that in some contexts, NRAS or FGFR1 mutations may also confer sensitivity to MAP kinase pathway inhibition, but that high p-ERK may correlate with insensitivity to these inhibitors. While these studies require functional validation, they demonstrate how cultured cell models facilitate orthogonal analyses of genomic and protein data to yield new insights into targeted therapeutic response. Overall, the large-scale application of these approaches to genetically annotated cancer cell culture models should provide a rich framework for extraction of key dependencies from tumor genomic data, thereby offering new therapeutic possibilities in melanoma and many other solid tumors.
Materials and Methods:
Cell culture and reagents.
Short-term melanoma cultures were selected from cryopreserved collections at the Wistar Institute (62 lines), the University Hospital of Zurich (24 lines 
High-density SNP array hybridization.
Genomic DNA was prepared from near-confluent cells using the DNEasy Tissue Kit (Qiagen)
according to the manufacturer's instructions. For highly pigmented cultures, 1:1 phenolcholoroform extractions followed by centrifugation were performed prior to column purification.
SNP array data was generated using either the StyI chip from the 500K Human Mapping Array set (Affymetrix, Inc.) (58 samples) or the XbaI chip from the 50K Human Mapping Array set (31 samples). Array experiments using 250 ng of genomic DNA were carried out in 96-well format using a Biomek FX robot with dual 96 and span-8 heads (Beckman Coulter) and a GeneChip Fluidics Station FS450 (Affymetrix, Inc.), as described in Supplementary Methods. After hybridization, microarrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix, Inc.) to generate .cel and .txt files. Subsequent data processing steps are detailed in Supplementary Methods.
High-throughput oncogene mutation profiling and DNA sequencing.
Genomic DNA was genotyped for 238 known mutations in 17 oncogenes as described previously. 21 Alternatively, BRAF and NRAS mutations were determined by Sanger sequencing (Agencourt). All samples were sequenced for PTEN coding and splice junction mutations using pre-validated exon primers (Agencourt) and analyzed with Mutation Surveyor (SoftGenetics, LLC.).
Gene expression profiling.
RNA was purified by a TRIzol extraction protocol (Invitrogen), as described in Supplementary Methods. Affymetrix HT-HGU133A chips were used for generation of gene expression data.
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With 2.5 µg of RNA, synthesis of the cRNA target product, hybridization to the microarray, and scanning of the arrays followed Affymetrix manufacturer's protocols. Reagents and products associated with the GeneChip assay were used in 96-well plate format and the plate was scanned with the Affymetrix HT scanner. Scanned data was converted to average difference values using MAS 5.0 (Affymetrix), as described in Supplementary Methods.
BAC array data processing.
Previously reported BAC array CGH primary melanoma data 26 was downloaded from the GEO database (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2631). The genomic markers were converted from hg16 to hg17 using the UCSC genome browser (http://genome.ucsc.edu/cgi-bin/hgLiftOver). Log 2 -ratio values were smoothed using the GLAD segmentation algorithm. BAC markers in regions of known copy number polymorphisms were removed (http://projects.tcag.ca/variation/) prior to downstream analysis.
Genomic Identification of Somatic Targets in Cancer (GISTIC) analysis.
Details of the GISTIC algorithm are described elsewhere (Beroukhim et al., submitted) . Briefly, each SNP array or CGH data set is defined in terms of copy-number values for N markers along the genome in M tumor samples. To identify significant regions of amplification and deletion, the GISTIC algorithm considers both the frequency F of an amplification or deletion above (or below) a certain threshold, and the amplitude of that alteration A beyond a certain threshold defined by normal samples. Thereby, a genome significance score (G score) G = F x A is defined over N markers for all M samples. At each marker n the computed metric G is compared to the null hypothesis -a background metric defined by permutation testing across all the markers. Correcting for multiple hypotheses, we generate a false-discovery rate (q-value) at each marker n, aggregating information from M samples. Using segmented copy number data from each sample, the minimal common region of overlap is used to define boundaries of peaks in the distribution of q-values. A "wide peak" boundary is determined by samples remaining after leaving out the individual samples that define the borders of the "narrow peak." This wide peak reduces the influence of individual samples in dictating peak borders.
Inference of Loss-of-heterozygosity.
A Hidden Markov Model from dChipSNP software (August 16, 2006 build) that considers haplotype information was used to infer LOH calls as described previously 30 (Supplementary Methods).
Hierarchical clustering using genomic alterations.
An input binary matrix generated from the GISTIC algorithm (see above). For each lesion defined by GISTIC, a "1" was assigned to a lesion i in a given sample j if the middle marker in the lesion i region exceeded the designated log 2 threshold of 0.3 for amplifications, or -0.3 for deletions. Otherwise, that cell ij was assigned a "0." Hierarchical clustering 42 with Euclidean distance and complete linkage was applied to this matrix using the GenePattern software package. 
Pharmacologic growth inhibition assays.
Cultured melanoma cells were added to 96-well plates at a concentration of 1,000 (A375 and MCF7) and 3,000 (all short-term melanoma cultures and the MALME 3M cell line) cells per well.
Cells were allowed to adhere overnight, and media containing serial dilutions of CI-1040 (from 100µM to 1x10 -6 µM) was added. Cells were incubated for 96 hours, at which time cell viability was measured using the CellTiter-Glo viability assay (Promega). Viability was calculated as a percentage of untreated control values after background subtraction.
Western blotting and biochemical studies. 
After cell lysis (Supplementary
